Suppr超能文献

比较用于存档福尔马林固定、石蜡包埋组织的信使核糖核酸表达谱分析的平台

Comparing Platforms for Messenger RNA Expression Profiling of Archival Formalin-Fixed, Paraffin-Embedded Tissues.

作者信息

Tyekucheva Svitlana, Martin Neil E, Stack Edward C, Wei Wei, Vathipadiekal Vinod, Waldron Levi, Fiorentino Michelangelo, Lis Rosina T, Stampfer Meir J, Loda Massimo, Parmigiani Giovanni, Mucci Lorelei A, Birrer Michael

机构信息

Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts.

Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

出版信息

J Mol Diagn. 2015 Jul;17(4):374-81. doi: 10.1016/j.jmoldx.2015.02.002. Epub 2015 Apr 30.

Abstract

Archival formalin-fixed, paraffin-embedded (FFPE) tissue specimens represent a readily available but largely untapped resource for gene expression profiling-based biomarker discovery. Several technologies have been proposed to cope with the bias from RNA cross-linking and degradation associated with archival specimens to generate data comparable with RNA from fresh-frozen materials. Direct comparison studies of these RNA expression platforms remain rare. We compared two commercially available platforms for RNA expression profiling of archival FFPE specimens from clinical studies of prostate and ovarian cancer: the Affymetrix Human Gene 1.0ST Array following whole-transcriptome amplification using the NuGen WT-Ovation FFPE System V2, and the NanoString nCounter without amplification. For each assay, we profiled 7 prostate and 11 ovarian cancer specimens, with a block age of 4 to 21 years. Both platforms produced gene expression profiles with high sensitivity and reproducibility through technical repeats from FFPE materials. Sensitivity and reproducibility remained high across block age within each cohort. A strong concordance was shown for the transcript expression values for genes detected by both platforms. We showed the biological validity of specific gene signatures generated by both platforms for both cohorts. Our study supports the feasibility of gene expression profiling and large-scale signature validation on archival prostate and ovarian tumor specimens using commercial platforms. These approaches have the potential to aid precision medicine with biomarker discovery and validation.

摘要

存档的福尔马林固定石蜡包埋(FFPE)组织标本是一种现成但尚未充分利用的资源,可用于基于基因表达谱的生物标志物发现。已经提出了几种技术来应对与存档标本相关的RNA交联和降解所带来的偏差,以生成与新鲜冷冻材料中的RNA可比的数据。对这些RNA表达平台的直接比较研究仍然很少。我们比较了两种用于前列腺癌和卵巢癌临床研究中存档FFPE标本RNA表达谱分析的商用平台:使用NuGen WT-Ovation FFPE System V2进行全转录组扩增后的Affymetrix Human Gene 1.0ST Array,以及未进行扩增的NanoString nCounter。对于每种检测方法,我们对7例前列腺癌和11例卵巢癌标本进行了分析,标本块龄为4至21年。通过对FFPE材料进行技术重复,两个平台均产生了具有高灵敏度和可重复性的基因表达谱。在每个队列中,不同块龄的样本灵敏度和可重复性均保持较高水平。两个平台检测到的基因的转录本表达值显示出很强的一致性。我们展示了两个平台为两个队列生成的特定基因特征的生物学有效性。我们的研究支持使用商用平台对存档的前列腺和卵巢肿瘤标本进行基因表达谱分析和大规模特征验证的可行性。这些方法有可能通过生物标志物的发现和验证来辅助精准医学。

相似文献

1
Comparing Platforms for Messenger RNA Expression Profiling of Archival Formalin-Fixed, Paraffin-Embedded Tissues.
J Mol Diagn. 2015 Jul;17(4):374-81. doi: 10.1016/j.jmoldx.2015.02.002. Epub 2015 Apr 30.
4
Preparation of archival formalin-fixed paraffin-embedded mouse liver samples for use with the Agilent gene expression microarray platform.
J Pharmacol Toxicol Methods. 2013 Sep-Oct;68(2):260-268. doi: 10.1016/j.vascn.2013.02.008. Epub 2013 Mar 1.

引用本文的文献

1
Intratumoral vitamin D signaling and lethal prostate cancer.
Carcinogenesis. 2024 Oct 10;45(10):735-744. doi: 10.1093/carcin/bgae055.
2
LINCATRA: Two-cycle method to amplify RNA for transcriptome analysis from formalin-fixed paraffin-embedded tissue.
Heliyon. 2024 Jun 12;10(12):e32896. doi: 10.1016/j.heliyon.2024.e32896. eCollection 2024 Jun 30.
3
Prognostic significance of EGFR, AREG and EREG amplification and gene expression in muscle invasive bladder cancer.
Front Oncol. 2024 May 28;14:1370303. doi: 10.3389/fonc.2024.1370303. eCollection 2024.
4
Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions.
Mol Cancer Res. 2023 Jan 3;21(1):14-23. doi: 10.1158/1541-7786.MCR-22-0446.
6
Gene Expression Pathways in Prostate Tissue Associated with Vigorous Physical Activity in Prostate Cancer.
Cancer Epidemiol Biomarkers Prev. 2021 Apr;30(4):751-756. doi: 10.1158/1055-9965.EPI-20-1461. Epub 2021 Jan 26.
7
Suppression of ARID1A associated with decreased CD8 T cells improves cell survival of ovarian clear cell carcinoma.
J Gynecol Oncol. 2021 Jan;32(1):e3. doi: 10.3802/jgo.2021.32.e3. Epub 2020 Oct 23.
8
ARHGEF38 as a novel biomarker to predict aggressive prostate cancer.
Genes Dis. 2019 Apr 3;7(2):217-224. doi: 10.1016/j.gendis.2019.03.004. eCollection 2020 Jun.
10
Expression Concordance of 325 Novel RNA Biomarkers between Data Generated by NanoString nCounter and Affymetrix GeneChip.
Dis Markers. 2019 May 14;2019:1940347. doi: 10.1155/2019/1940347. eCollection 2019.

本文引用的文献

1
Long-term impact of the 70-gene signature on breast cancer outcome.
Breast Cancer Res Treat. 2014 Feb;143(3):587-92. doi: 10.1007/s10549-013-2831-4. Epub 2014 Jan 21.
2
Gene expression, single nucleotide variant and fusion transcript discovery in archival material from breast tumors.
PLoS One. 2013 Nov 22;8(11):e81925. doi: 10.1371/journal.pone.0081925. eCollection 2013.
6
Expression profiling of archival tumors for long-term health studies.
Clin Cancer Res. 2012 Nov 15;18(22):6136-46. doi: 10.1158/1078-0432.CCR-12-1915. Epub 2012 Nov 7.
7
The mutational landscape of lethal castration-resistant prostate cancer.
Nature. 2012 Jul 12;487(7406):239-43. doi: 10.1038/nature11125.
9
Preparing for precision medicine.
N Engl J Med. 2012 Feb 9;366(6):489-91. doi: 10.1056/NEJMp1114866. Epub 2012 Jan 18.
10
Incorporation of bevacizumab in the primary treatment of ovarian cancer.
N Engl J Med. 2011 Dec 29;365(26):2473-83. doi: 10.1056/NEJMoa1104390.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验